Peggy Sextius

Peggy Sextius

Auto-generated profile, based on publicly available information

Peggy Sextius

L'Oréal Research and Innovation, 1, Avenue Eugène Schueller, 93601, Aulnay-Sous-Bois, France

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 February 2024 in Journal of Cosmetic Dermatology
Verified
Journal Article
Open access
RDR. de Dormael
R. de Dormael
PSP. Sextius
P. Sextius
NBN. Bourokba
N. Bourokba
EME. Mainguene
E. Mainguene
RTR. Tachon
R. Tachon
SDS. Diridollou
S. Diridollou
Background: Chronic nonextreme sun exposure induces two mechanisms of skin pigmentation, causing immediate darkening and delayed tanning. A new molecule, 2‐mercaptonicotinoyl glycine (2‐MNG), has been shown in vitro to inhibit both immediate darkening and new melanin synthesis via covalent conjugation of the thiol group of 2‐MNG to melanin precursors. Objective: To evaluate 2‐MNG in preventing both mechanisms in vivo. Methods: In a randomized, intra‐individual and controlled study, 33 subjects with melanin‐rich skin were exposed to UV daylight on designated areas on the back and treated with a cosmetic formula containing 0.5% or 1% 2‐MNG alone or 0.5% 2‐MNG in association with lipohydroxy acid (LHA, 0.3%) plus Mexoryl‐SX (MSX, 1.5%). The respective vehicles were used as controls and 4‐n‐butyl‐resorcinol (4‐n‐BR, 2.5%) as a positive reference. Results: 2‐MNG alone significantly reduced immediate darkening and inhibited new melanin production when compared with vehicle, with higher performance at 1% than at 0.5%. 2‐MNG at 0.5% in association with LHA and MSX showed significantly higher performance than 2‐MNG 0.5% alone. 2‐MNG at 0.5% and 1% showed significantly better performance than 4‐n‐BR. Conclusions: 2‐MNG inhibited both UV‐induced skin pigmentation mechanisms in vivo. The association of 2‐MNG with LHA plus MSX showed the highest efficacy on melanin‐rich skin with pigmentation induced by UV exposure.

1 April 2024 in Pigment Cell & Melanoma Research
Verified
Journal Article
Open access
PSPeggy Sextius
Peggy Sextius
EWEmilie Warrick
Emilie Warrick
APAmélie Prévot‐Guéguiniat
Amélie Prévot‐Guéguiniat
GLGuillaume Lereaux
Guillaume Lereaux
FBFlorence Boirre
Florence Boirre
XMXavier Marat
Xavier Marat
Research on new ingredients that can prevent excessive melanin production in the skin while considering efficacy, safety but also environmental impact is of great importance to significantly improve the profile of existing actives on the market and avoid undesirable side effects. Here, the discovery of an innovative technology for the management of hyperpigmentation is described. High‐throughput screening tests on a wide chemical diversity of molecules and in silico predictive methodologies were essential to design an original thiopyridinone backbone and select 2‐mercaptonicotinoyl glycine (2‐MNG) as exhibiting the most favorable balance between the impact on water footprint, skin penetration potential and performance. The effectiveness of 2‐MNG was confirmed by topical application on pigmented reconstructed epidermis and human skin explants. In addition, experiments have shown that unlike most melanogenesis inhibitors on the market, this molecule is not a tyrosinase inhibitor. 2‐MNG binds to certain melanin precursors, preventing their integration into growing melanin and leading to inhibition of eumelanin and pheomelanin synthesis, without compromising the integrity of melanocytes.

3 June 2026 in Dermatology and Therapy
Verified
Journal Article
Open access
CDChristine Duval
Christine Duval
JQJie QIU
Jie QIU
EWEmilie Warrick
Emilie Warrick
PSPeggy Sextius
Peggy Sextius
ICIsabelle Castiel-Higounenc
Isabelle Castiel-Higounenc
TPThierry PASSERON
Thierry PASSERON
Hyperpigmentation disorders affect a large proportion of the population, significantly impacting their quality of life and carrying considerable social stigma. This growing global concern results in a strong demand for effective treatments. A rich body of literature proposes numerous active ingredients to solve hyperpigmentation concerns. At the same time, the complex regulation of skin pigmentation is much better understood with increased knowledge on the physiopathology of pigmentary disorders, beyond the sole melanogenesis, including the whole tissue environment of melanocytes. The abundance of mechanistic in vitro and in vivo scientific data makes it challenging for non-expert clinicians to identify the optimal care for patients. The aim of this review is to propose state-of-the-art of topical solutions with actives that have demonstrated conclusive clinical efficacy. It analyzes the different mechanisms involved, including the melanogenesis pathway and others addressing the melanocyte microenvironment. This review first examines the prevention of pigmentary disorders and the importance of a broad-spectrum photoprotection including the whole UV spectrum but also visible light in managing hyperpigmentation. The use of antioxidants to combat oxidative stress and complement photoprotection is also discussed. The following section reviews actives targeting the modulation of melanogenesis. It examines tyrosinase inhibitors, which are still widely used to manage hyperpigmentation problems, as well as new compounds targeting downstream pathways. Other clinically effective interventions include the normalization of epidermal homeostasis and the active restoration of the dermal fibroblastic microenvironment, together with anti-inflammatory agents and those aimed at reducing vascularization impact. Finally, this review highlights the value of combined approaches which have been shown to improve clinical efficacy. This suggests that future research should focus on well-tolerated, multifaceted therapies to effectively treat melanin hyperpigmentary disorders.